New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug
This article was originally published in PharmAsia News
New Zealand's Pharmac said the drug-coverage agency is weighing the $421,000-a-year cost against the benefits of subsidizing Alexion's Soliris (eculizumab) in treating to a rare type of hemophilia.
You may also be interested in...
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.
The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.